ID: ALA4162182

Max Phase: Preclinical

Molecular Formula: C25H23F6N3O2

Molecular Weight: 511.47

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)c1c(N2CCCC2)c2ccccc2n(C)c1=O

Standard InChI:  InChI=1S/C25H23F6N3O2/c1-32(14-15-11-16(24(26,27)28)13-17(12-15)25(29,30)31)22(35)20-21(34-9-5-6-10-34)18-7-3-4-8-19(18)33(2)23(20)36/h3-4,7-8,11-13H,5-6,9-10,14H2,1-2H3

Standard InChI Key:  MCDADOMPEINVRO-UHFFFAOYSA-N

Associated Targets(Human)

Phosphatidylcholine:ceramide cholinephosphotransferase 2 194 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HEK-293T 167025 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphatidylcholine:ceramide cholinephosphotransferase 1 149 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Phosphatidylcholine:ceramide cholinephosphotransferase 2 21 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 511.47Molecular Weight (Monoisotopic): 511.1694AlogP: 5.45#Rotatable Bonds: 4
Polar Surface Area: 45.55Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: CX LogP: 4.00CX LogD: 4.00
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.44Np Likeness Score: -1.17

References

1. Adachi R, Ogawa K, Matsumoto SI, Satou T, Tanaka Y, Sakamoto J, Nakahata T, Okamoto R, Kamaura M, Kawamoto T..  (2017)  Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.,  136  [PMID:28505533] [10.1016/j.ejmech.2017.04.067]
2. Yukawa T, Nakahata T, Okamoto R, Ishichi Y, Miyamoto Y, Nishimura S, Oikawa T, Kubo K, Adachi R, Satomi Y, Nakakariya M, Amano N, Kamaura M, Matsunaga N..  (2020)  Discovery of 1,8-naphthyridin-2-one derivative as a potent and selective sphingomyelin synthase 2 inhibitor.,  28  (7): [PMID:32088125] [10.1016/j.bmc.2020.115376]

Source